Collaborations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended	12 Months Ended
	Jul. 06, 2021	Jul. 07, 2020	May 09, 2019	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cost reimbursement payment received					$ 13,800	$ 6,700
Unbilled accounts receivable				$ 3,800	$ 3,800	2,500
Remaining research term of collaboration					3 years
Aggregate proceeds from issuance of private placement						174
Revenue recognized					$ 78,592	46,826	$ 72,832
Research and development					189,081	164,248	137,017
Milestone 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized recorded in deferred revenue				40,300
Deferred revenue				14,700	14,700
Unconstrained consideration				55,000	55,000
Private Placement | Vertex Pharmaceuticals Incorporated
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of shares, Shares	49,928
Common stock per share	$ 47
Aggregate proceeds from issuance of private placement	$ 2,300
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment		$ 150,000
Collaboration agreement transaction price		150,000
Revenue recognized recorded in deferred revenue					70,200	36,000
Unsatisfied performance obligation				54,700	54,700	54,900
Revenue recognized					70,200	19,000	54,300
Sanofi Agreement | Milestone 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones Revenue Recognized				40,000
Sanofi Agreement | Milestone 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones Revenue Recognized				15,000
Sanofi Agreement | Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price		120,000
Revenue recognized recorded in deferred revenue					67,700	19,400
Milestone receivable				15,000	15,000
Milestones Received Amount				40,000	40,000
Revenue recognized							45,500
Sanofi Agreement | Collaboration Target 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price		30,000
Revenue recognized recorded in deferred revenue					2,500	16,600
Revenue recognized							8,800
Sanofi Agreement | Minimum | IRAK4 Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments		1,000,000
Commercial milestone payments		400,000
Sanofi Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments		1,480,000
Commercial milestone payments		$ 700,000
Vertex Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized recorded in deferred revenue					8,400
Unsatisfied performance obligation				$ 0	0	8,400
Initial research term of collaboration			4 years
Extended research term of collaboration			1 year
Revenue recognized					$ 8,400	$ 10,800	$ 18,500
Vertex Agreement | Series B-1 Convertible Preferred
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price			$ 55,900
Non refundable upfront payment received			$ 50,000
Issuance of shares, Shares			3,059,695
Preferred stock premium			$ 5,900
Vertex Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive payments including development, regulatory and commercial milestones			$ 170,000